about
A decrease in drug resistance levels of the HIV epidemic can be bad newsPreexposure chemoprophylaxis for HIV prevention in men who have sex with menRandomized, controlled trial of therapy interruption in chronic HIV-1 infectionIntegrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early TreatmentPatterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practicesHIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA PanelTenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trialTarget cell APOBEC3C can induce limited G-to-A mutation in HIV-1Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San FranciscoSentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infectionThe potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling studyNo evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxisStrong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menImmunity to HIV-1 is influenced by continued natural exposure to exogenous virus.Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with menBrief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis TrialWhither or wither microbicides?A tale of two futures: HIV and antiretroviral therapy in San Francisco.HIV RNA level in early infection is predicted by viral load in the transmission source.Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions.Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study.Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionHuman immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with menEffectiveness and safety of oral HIV preexposure prophylaxis for all populationsStreamlining HIV testing for HIV preexposure prophylaxis.Accuracy of the TRUGENE HIV-1 genotyping kit.Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease geneDifferential persistence of transmitted HIV-1 drug resistance mutation classes.Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trialCellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco.
P50
Q23917626-7FF7141E-A395-41CB-A73D-78716A8C23CFQ24612082-94B28146-3AD2-49FD-8303-CAB5876AD543Q24809608-D92F53A9-A3D3-4AA4-923B-5DE31705776CQ26778085-D722F5A9-6430-4DA0-9CF9-50EC9F625246Q27313352-F782C6E9-6D78-430A-BD32-91546F038A9CQ28072780-B4FD4285-651B-4499-AAB1-69C765966114Q28244216-E2F181FD-A2E1-48F7-8244-EDAA00B0ED40Q28469218-E8D9B294-159B-4DDD-AFA8-05AB5C3B0174Q28469342-4D04C49E-0CD4-4C9E-A127-A02E58FD3A9DQ28476489-C6C16B30-2C1E-4FAB-A862-DD0B059A0A9DQ28476730-EA6846CC-BD6F-42FE-9226-B27968B1CB41Q28477399-F5D67D82-1BC0-421A-A318-66643C762C0AQ28484308-C14E21E7-097C-40B3-B943-6F9940A9EF7AQ28537713-591A77D4-B0A4-4533-85C9-C913A72CAA65Q28538457-B5516ABB-612D-4FD5-AE1C-B30AED294063Q28540969-2061902A-3527-4568-B09C-AF0799979E52Q33379075-72A9EB55-CA1F-4702-8199-CF1847D8B509Q33526254-0CC64A56-0AA6-4798-849E-1B2DBF859E1CQ33574027-1823A37C-6185-4809-9E3B-AFABCF45BAABQ33715907-E54EE3D7-60A0-490F-BFEE-63E7B7637FC0Q33887969-9225A93B-9F12-49F3-8E25-38D02E70441CQ33921382-17BFD187-F342-4E17-B5D4-51D7B91CB162Q33934337-5257FDA0-9E66-43EA-985B-5DDF233C4BE2Q33948938-F4EDE7DF-AD4D-4B73-87B5-9803DF6FE908Q34046430-FB9EAF3F-5CF0-41A2-9902-A1B292CD9C58Q34182965-83D77805-11F6-4894-A7BE-FE51DA600628Q34202159-A214B560-F683-47E6-8413-FF890D47EE97Q34249966-0BDEB378-4DB8-47E4-B84B-81F59B0D64D9Q34342894-654B9BA5-116A-4315-A4FD-20B021689899Q34481359-9EC604F0-51B7-4F8F-80B9-AAE909279764Q34553124-41F1A3C9-764A-42E6-B659-67203DA778F7Q34584208-C8AC3A1E-7EE2-4818-BFB4-6378DB5A4260Q34677217-E73752EE-6E66-4C59-A43D-68E2DD80D6BEQ34916430-24BDDE05-C0E9-45C3-9F02-C75D62DC02D6Q34972796-60C8035A-2300-483D-88F4-F788CA2547D2Q35020128-93F912EA-6858-4784-8369-48F9645C6259Q35022802-3CC179B2-8328-4C5E-9ABB-5EEC352FCE08Q35752303-328A2342-5261-4FD3-AA72-025A07D7B0A9Q35845726-6D3F5609-BD1A-4139-A69C-7FCE1033515CQ35850405-75CCE5FA-5D30-403D-9CA5-94BB2A6CDDF5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert M. Grant
@ast
Robert M. Grant
@en
Robert M. Grant
@es
Robert M. Grant
@nl
Robert M. Grant
@sl
type
label
Robert M. Grant
@ast
Robert M. Grant
@en
Robert M. Grant
@es
Robert M. Grant
@nl
Robert M. Grant
@sl
altLabel
Robert Grant
@en
prefLabel
Robert M. Grant
@ast
Robert M. Grant
@en
Robert M. Grant
@es
Robert M. Grant
@nl
Robert M. Grant
@sl
P106
P1153
7402006018
P21
P31
P496
0000-0002-0851-7085